A dermatological perspective: eosinophilic eruption of hematoproliferative disease as a clinical and histological dilemma.

IF 0.6 Q4 DERMATOLOGY
Tijana Orlic, Snezana Minic, Emilija Manojlovic-Gacic, Dubravka Zivanovic, Igor Kapetanovic
{"title":"A dermatological perspective: eosinophilic eruption of hematoproliferative disease as a clinical and histological dilemma.","authors":"Tijana Orlic, Snezana Minic, Emilija Manojlovic-Gacic, Dubravka Zivanovic, Igor Kapetanovic","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The emergence of de novo or recurrent cutaneous eruptions in individuals with hematological diseases presents a challenge when determining whether they indicate secondary dissemination or an unrelated diagnosis. Eosinophilic eruption of hematoproliferative disease is a rare nonspecific manifestation accompanying lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL). We present the case of a 70-year-old man with CLL in remission (previously treated with two 6-month cycles of fludarabine-cyclophosphamide plus rituximab, 2 and 5 years earlier) with an acute, disseminated polymorphic skin eruption. Skin biopsies from two sites (bulla and infiltrated nodule) were taken for histopathological examination. The pathologist reported giant spongiform vesicle formation with eosinophils with dermal and hypodermal inflammatory infiltrate composed of lymphocytes (predominantly T cells, fewer B cells) and eosinophils. Secondary neoplasm dissemination and sarcoidosis were excluded by means of immunohistochemistry. A diagnosis of eosinophilic eruption of hematoproliferative disease in the CLL patient post-chemotherapy and without active disease was established. Two weeks after skin remission, the patient worsened with enlarged lymph nodes and a leukocyte count of 291 × 10^9/l. CLL relapse was confirmed. Leukocytapheresis was performed and ibrutinib 140 mg three times daily was prescribed. Our case underscores the importance of recognizing this relatively common but underreported eosinophilic eruption associated with hematoproliferative diseases.</p>","PeriodicalId":45914,"journal":{"name":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","volume":"32 4","pages":"183-186"},"PeriodicalIF":0.6000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Dermatovenerologica Alpina Pannonica et Adriatica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The emergence of de novo or recurrent cutaneous eruptions in individuals with hematological diseases presents a challenge when determining whether they indicate secondary dissemination or an unrelated diagnosis. Eosinophilic eruption of hematoproliferative disease is a rare nonspecific manifestation accompanying lymphoproliferative disorders, including chronic lymphocytic leukemia (CLL). We present the case of a 70-year-old man with CLL in remission (previously treated with two 6-month cycles of fludarabine-cyclophosphamide plus rituximab, 2 and 5 years earlier) with an acute, disseminated polymorphic skin eruption. Skin biopsies from two sites (bulla and infiltrated nodule) were taken for histopathological examination. The pathologist reported giant spongiform vesicle formation with eosinophils with dermal and hypodermal inflammatory infiltrate composed of lymphocytes (predominantly T cells, fewer B cells) and eosinophils. Secondary neoplasm dissemination and sarcoidosis were excluded by means of immunohistochemistry. A diagnosis of eosinophilic eruption of hematoproliferative disease in the CLL patient post-chemotherapy and without active disease was established. Two weeks after skin remission, the patient worsened with enlarged lymph nodes and a leukocyte count of 291 × 10^9/l. CLL relapse was confirmed. Leukocytapheresis was performed and ibrutinib 140 mg three times daily was prescribed. Our case underscores the importance of recognizing this relatively common but underreported eosinophilic eruption associated with hematoproliferative diseases.

皮肤病学视角:血液增生性疾病的嗜酸性粒细胞爆发是临床和组织学难题。
血液病患者出现新发或复发的皮肤糜烂,给确定其是否预示着继发性传播或非相关诊断带来了挑战。血液增生性疾病的嗜酸性粒细胞疹是淋巴增生性疾病(包括慢性淋巴细胞白血病(CLL))伴随的一种罕见的非特异性表现。我们介绍了一例 70 岁的慢性淋巴细胞白血病缓解期男性患者(曾在 2 年前和 5 年前接受过两个 6 个月周期的氟达拉滨-环磷酰胺加利妥昔单抗治疗)的病例,患者出现急性、播散性多形性皮肤糜烂。从两个部位(鼓包和浸润性结节)取皮肤活检进行组织病理学检查。病理学家报告说,巨大的海绵状囊泡与嗜酸性粒细胞形成,真皮和皮下炎症浸润由淋巴细胞(主要是 T 细胞,B 细胞较少)和嗜酸性粒细胞组成。通过免疫组化检查,排除了继发性肿瘤扩散和肉样瘤病的可能性。化疗后无活动性疾病的 CLL 患者嗜酸性粒细胞爆发性血液增生性疾病的诊断成立。皮肤缓解两周后,患者病情恶化,淋巴结肿大,白细胞计数达到 291 × 10^9/l。确诊为 CLL 复发。患者接受了白细胞清除术,并服用了伊布替尼 140 毫克,每日三次。我们的病例强调了认识这种与血液增生性疾病相关的相对常见但报告不足的嗜酸性粒细胞爆发的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
8.30%
发文量
38
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信